EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Avapritinib versus Placebo in Indolent Systemic Mastocytosis

Jason Gotlib, Mariana Castells, Hanneke Oude Elberink, Frank Siebenhaar, Karin Hartmann, Sigurd Broesby-Olsen, Tracy I George, Jens Panse, Iván Alvarez-Twose, Deepti H Radia, Tsewang Tashi, Cristina Bulai Livideanu und 41 weitere

NEJM Evidence · 2023

DOI: 10.1056/evidoa2200339 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift NEJM Evidence, 2023. Verfasst von Jason Gotlib und 52 weiteren Autor:innen. Beteiligte Einrichtung: Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA. Hauptthemen laut MEDLINE: Mastocytosis, Systemic. Die Arbeit wurde bisher 77-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Indolent systemic mastocytosis (ISM) is a clonal mast-cell disease driven by the KIT D816V mutation. We assessed the efficacy and safety of avapritinib versus placebo, both with best supportive care, in patients with ISM. METHODS: We randomized patients with moderate to severe ISM (total symptom score [TSS] of ≥28; scores range from 0 to 110, with higher numbers indicating more severe symptoms) two to one to avapritinib 25 mg once daily (n=141) or placebo (n=71). The primary end point was mean change in TSS based on the 14-day average of patient-reported severity of 11 symptoms. Secondary end points included reductions in serum tryptase and blood KIT D816V variant allele fraction (≥50%), reductions in TSS (≥50% and ≥30%), reduction in bone marrow mast cells (≥50%), and quality of life measures. RESULTS: From baseline to week 24, avapritinib-treated patients had a decrease of 15.6 points (95% CI, −18.6 to −12.6) in TSS compared to a decrease of 9.2 points (−13.1 to −5.2) in the placebo group; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mastocytosis, SystemicHumansPyrazolesPyrrolesTriazinesAvapritinib

Substanzen

PyrazolesPyrrolesTriazinesAvapritinib

Autor:innen und Institutionen

  • Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA.
  • Department of Medicine, Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Harvard Medical School, Boston.
  • Department of Allergology, University Medical Center, Groningen Research Institute Asthma and COPD, University of Groningen, Groningen, the Netherlands.
  • Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin.
  • Fraunhofer Institute for Translational Medicine and Pharmacology, Allergology and Immunology, Berlin.
  • Division of Allergy, Department of Dermatology, University Hospital Basel and University of Basel, Basel, Switzerland.

Zitieren

APA

Gotlib, J., Castells, M., Elberink, H. O., Siebenhaar, F., Hartmann, K., Broesby-Olsen, S., George, T. I., Panse, J., Alvarez-Twose, I., Radia, D. H., Tashi, T., Bulai Livideanu, C., Sabato, V., Heaney, M., Van Daele, P., Cerquozzi, S., Dybedal, I., Reiter, A., Pongdee, T., …, & Maurer, M. (2023). Avapritinib versus Placebo in Indolent Systemic Mastocytosis. NEJM Evidence. https://doi.org/10.1056/evidoa2200339

Vancouver

Gotlib J, Castells M, Elberink HO, Siebenhaar F, Hartmann K, Broesby-Olsen S, et al. Avapritinib versus Placebo in Indolent Systemic Mastocytosis. NEJM Evidence. 2023. doi:10.1056/evidoa2200339

BibTeX
@article{Gotlib2023,
  author = {Gotlib, Jason and Castells, Mariana and Elberink, Hanneke Oude and Siebenhaar, Frank and Hartmann, Karin and Broesby-Olsen, Sigurd and George, Tracy I and Panse, Jens and Alvarez-Twose, Iván and Radia, Deepti H and Tashi, Tsewang and Bulai Livideanu, Cristina and Sabato, Vito and Heaney, Mark and Van Daele, Paul and Cerquozzi, Sonia and Dybedal, Ingunn and Reiter, Andreas and Pongdee, Thanai and Barete, Stéphane and Ustun, Celalettin and Schwartz, Lawrence and Ward, Brant R and Schafhausen, Philippe and Vadas, Peter and Bose, Prithviraj and DeAngelo, Daniel J and Rein, Lindsay and Vachhani, Pankit and Triggiani, Massimo and Bonadonna, Patrizia and Rafferty, Mark and Butt, Nauman M and Oh, Stephen T and Wortmann, Friederike and Ungerstedt, Johanna and Guilarte, Mar and Taparia, Minakshi and Kuykendall, Andrew T and Arana Yi, Cecilia and Ogbogu, Princess and Gaudy-Marqueste, Caroline and Mattsson, Mattias and Shomali, William and Giannetti, Matthew P and Bidollari, Ilda and Lin, Hui-Min and Sulllivan, Erin and Mar, Brenton and Scherber, Robyn and Roche, Maria and Akin, Cem and Maurer, Marcus},
  title = {Avapritinib versus Placebo in Indolent Systemic Mastocytosis},
  journal = {NEJM Evidence},
  year = {2023},
  doi = {10.1056/evidoa2200339}
}
Kostenlos starten →